Prelude Capital Management’s Puma Biotechnology PBYI Stock Holding History

Prelude Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$118K	Sell	18,448 -13,700	-43%	-$88.3K	0.01%	1023
2025 Q4	$191K	Sell	32,148 -6,274	-16%	-$33.3K	0.01%	1077
2025 Q3	$204K	Buy	38,422 +5,000	+15%	+$21.2K	0.02%	937
2025 Q2	$115K	Sell	33,422 -4,278	-11%	-$13.7K	0.01%	887
2025 Q1	$112K	Buy	37,700 +12,900	+52%	+$40.4K	0.01%	1026
2024 Q4	$75.6K	Buy	+24,800	New	+$72.2K	﹤0.01%	1122
2019 Q3	–	Sell	-120	Closed	-$2K	–	1957
2019 Q2	$2K	Sell	120 -280	-70%	-$6.45K	﹤0.01%	1574
2019 Q1	$16K	Hold	400	–	–	﹤0.01%	1349
2018 Q4	$8K	Buy	+400	New	+$12K	﹤0.01%	1424
2018 Q2	–	Sell	-8,723	Closed	-$594K	–	1870
2018 Q1	$594K	Sell	8,723 -3,636	-29%	-$272K	0.04%	398
2017 Q4	$1.22M	Buy	+12,359	New	+$1.38M	0.1%	213
2017 Q2	–	Sell	-20,335	Closed	-$756K	–	1785
2017 Q1	$756K	Buy	+20,335	New	+$742K	0.07%	274
2015 Q3	–	Sell	-1,689	Closed	-$197K	–	1708
2015 Q2	$197K	Hold	1,689	–	–	0.03%	603
2015 Q1	$399K	Buy	+1,689	New	+$361K	0.06%	406

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Prelude Capital Management's PBYI Position: Q1 2026 in Review

Prelude Capital Management reduced its Puma Biotechnology (PBYI) stake by 43% in Q1 2026, selling an estimated $88.3K and leaving 18,448 shares worth $118K. The position accounts for 0.01% of the portfolio, ranked #1023.

Prelude Capital Management first reported a position in PBYI in Q1 2015 and has held it in 14 quarters since. The position peaked at $1.22M in Q4 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

Prelude Capital Management held 18,448 shares of Puma Biotechnology worth $118K as of Q1 2026.
Prelude Capital Management sold 13,700 Puma Biotechnology shares in Q1 2026, an estimated $88.3K.
Puma Biotechnology made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1023 holding.
Prelude Capital Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 14 quarters since.
Prelude Capital Management's Puma Biotechnology position peaked at $1.22M in Q4 2017.
157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.